0.00Open1.65Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover3010.65%IV-0.26%PremiumDec 27, 2024Expiry Date1.72Intrinsic Value100Multiplier-14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9456Delta0.1032Gamma16.19Leverage Ratio-87.2470Theta0.0000Rho15.31Eff Leverage0.0000Vega
Pfizer Stock Discussion
Pfizer Inc (NYSE:PFE) shares are just "too low to sell," according to Jim Cramer, host of CNBC's "Mad Money Lightning Round."
Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" on the Seagen acquisition.
Pfizer stock is down more than 7% over the past year. With the Covid wave having past, the pharma giant is in talks to extend its collaboration with medical AI start-up firm PostEra to design antibody-drug conjugates.
Pfizer Inc. (NYSE:PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically me...
ok
buying time
Once the profit taking is over, the stock will rebound. Covid is here to stay and vaccines will always be needed.
No comment yet